Vinorelbine (VNB) + ifosfamide (IFX) in non operable non small cell lung cancer (NSCLC). A phase II study

Rivero, Oscar; Lozano, María Dolores; Polera, J.; Matiewjuk, M.; Bonicatto, S.; Callejas, Cristina González; Torello, E; Comba, Alberto Zori; Lewi, Daniel; Schmilovich, A.

doi:10.1016/s0959-8049(99)81459-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last few years., the advent of new drugs., such as vinorelbine or gemcitabine., better tolerated than cisplatin., has led investigators to the identification of active., non-cisplatin-containing regimens for advanced NSCLC. Vinorelbine plus ifosfamide chemotherapy has been widely investigated in phase I/II trials., reporting OR ranging from 28 to 40% and MST from 7.4 to 11.5 months [113][114][115][116][117][118]. However., in our opinion., ifosfamide requires adequate hydration and uroprotection with MESNA (2-mercaptoethanesulfonate) thus reducing the manageability of this combination.…”

Section: Non-platin-based Combination Chemotherapymentioning

confidence: 99%

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Gridelli¹,

Vivo

2002

CMC

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains a fatal disease: the majority of patients are diagnosed as having metastases or advanced inoperable tumors. The activity of chemotherapy in NSCLC patients is low with objective response rarely complete and sustained. Cisplatin-based combinations are considered as the standard chemotherapy treatment. Recently., the introduction of new and less toxic chemotherapeutic agents., such as vinorelbine., has led investigators to research for active non-cisplatin-containing combinations to treat patients with advanced disease having as primary needs symptom relief and an acceptable quality of life. This review will focus on the pharmacological properties of vinorelbine and its role in adjuvant chemotherapy., in combined chemo-radiotherapy., in advanced disease and in the particular setting of the elderly. The oral use of vinorelbine will be among the future developments of this drug.

show abstract

Section: Non-platin-based Combination Chemotherapymentioning

confidence: 99%